Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543335 · ClinicalTrials.gov registry record · Phase 1
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00543335: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00543335 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00543335, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with radiation therapy to people with lung cancer. The ability of both the study drug and radiation to control the disease will also be studied.
Interventions
- DRUG Sorafenib
- PROCEDURE Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-01-25 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543335
The ClinicalTrials.gov registry entry for NCT00543335 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00543335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543335 about?
NCT00543335 is a clinical study titled "Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer". The goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with radiation therapy to people with lung cancer. The ability of both the study drug and radiation to control the disease will also be studied.
What is the current status of trial NCT00543335?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-01-25. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00543335?
The interventions under investigation include: Sorafenib (DRUG), Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00543335?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.